For citations:
Breder VV, Pokataev IA, Petkau VV, Fedyanin MY, Ledin EV, Zagainov VE, Shapoval SV, Granov DA, Balakhnin PV, Kudashkin NE, Pogrebnyakov IV, Popova NV, Moroz EA. Advisory board resolution: The role of the adjuvant atezolizumab plus bevacizumab in patients with hepatocellular carcinoma at high risk of recurrence following surgical resection or ablation. Meditsinskiy sovet = Medical Council. 2023;(22):20-28. (In Russ.) https://doi.org/10.21518/ms2023-450